The growth and spread of malignant cells from primary tumor deposits is dependent upon the degree of vascularization provided by host vessels.
The growth and spread of malignant cells from primary tumor deposits is dependent upon the degree of vascularization provided by host vessels. 1 The control of angiogenesis and the biochemistry of each step of the process are areas of intense investigation since the ability to inhibit capillary growth has the potential of arresting progression of solid tumors without the induction of cancer cell-associated drug resistance. 2 The success of anti-angiogenic strategies is limited both by the redundancy of molecular targets implicated in initial stages of angiogenesis 3 and by the heterogeneity of cells that form the vascular wall. [4] [5] [6] Having developed a potentially therapeutic anti-angiogenic molecule, the ensuing challenge is to deliver the agent to the tumor in sufficient quantities for a sufficient period of time to significantly impact on neovascularization within the tumor. 7 ECM is widely accepted to play a central role in different steps of the angiogenic process, and constitutes an unexplored target for anti-angiogenic therapy. Basement membrane (BM) deposition is known to be crucial in the functional organization and maturation of newly formed vessels, and recently it has proved to be essential for vas- culogenic mimicry displayed by aggressive melanoma cells. 5 Furthermore, matrices conditioned by aggressive melanoma cells induce tube formation by poorly aggressive tumor cells, suggesting that instructional information is deposited into the ECM. 8 In fact it has been shown that aggressive melanoma cells form laminin-rich patterned networks on three-dimensional cultures. 8 Based on these considerations we have chosen laminin, a BM component with a well-known role in tube formation, 9, 10 as the target for antiangiogenic therapy.
We have reported the generation and characterization of a panel of human-derived scFvs specific for native laminin epitopes obtained by phage display technology.
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Soluble scFvs were produced as described 12 and purified by immobilized metal ion affinity chromatography (IMAC). Most of the antibodies reduced cell attachment to laminin, suggesting that domains of the molecule that are recognized by these phage antibodies most likely bind to cell-surface receptors. 11 Here, we have explored the behavior of several scFv clones in an in vitro morphogenesis assay during which endothelial cells plated on ECM preparations, such as Matrigel, spontaneously aggregate and assemble into multicellular capillary-like structures (CLS). This process has been suggested to represent the terminal stages of angiogenesis including branching, migration and differentiation. 10 Most of the anti-laminin scFvs did not alter CLS formation by HMEC-1 cells, a human microvascular endothelial cell line that exhibits phenotypic and functional characteristics of normal microvascular endothelial cells. 13 However, when L36 antibody was added endothelial cell assembly into tubular structures was strongly inhibited (Figure 1a .5). The cells still attached to Matrigel, but they assumed a flattened monolayer resembling the morphology of cells plated on plastic rather than aggregating into characteristic CLS (Figure 1a.1 and a.5) . Identical results were obtained with cultures of primary human umbilical-vein endothelial cells (HUVECs) (Figure 1b.3) . Control scFv specific for the hapten NIP (clone B1. 8 14 ), had no effect on endothelial cell CLS formation ( Figure  1a .8 and 1b.2). Quantitation of tubular structures by light microscopy, using the AD software, 15 revealed a dosedependent effect (Figure 1c ). Morphological effects were not observed on tissue culture plastic or on gels of purified ECM proteins such as collagen I (data not shown).
To evaluate whether L36 scFv antibody could block angiogenesis in vivo, we used a modified chicken chorioallantoic membrane (CAM) assay. 16 Basically, eggs containing developing embryos were treated with the test reagents, incubated and vascularization of the CAM was determined under the microscope. Figure 1d shows representative CAM images subjected to different treatments. When compared with eggs treated with the irrelevant antibody B1.8 (or PBS; data not shown), eggs treated with L36 exhibited a remarkable delay in the general development of the capillary network, with a decreased blood vessel/area ratio ( Figure 1d ). The few vessels remaining appeared irregular and discontinuous.
Previously we had demonstrated that L36 scFv anti- body shows strong immunohistochemical reactivity with BMs surrounding blood vessels in normal human and murine tissue sections. 11 To determine whether L36 recognizes the laminin isoforms present in the BM of tumor vasculature, we analyzed histological sections derived from Lewis lung carcinoma (LLC) tumor masses. Paraffin-embedded sections from different tumor specimens were processed as described. 17 As shown in Figure  2a , L36 localized to the vascular-associated BMs in established murine tumors. No reactivity was observed among BM surrounding vascular cells when L36 was omitted or when a control scFv was used (data not shown).
Figure 1 (a) Light microscopic photos of HMEC-1 cells plated for 16 h on either plastic (1) or a Matrigel monolayer (Becton
Next we investigated whether L36 scFv could inhibit the establishment and growth of tumors in an in vivo tumor transplantable model. LLC cells were injected in the subcutaneous dorsal space of immunocompetent C57BL/6 mice. Monovalent antibody fragments have relatively high off-rates due to single binding site and clear rapidly from the blood due to their small size. 18 Therefore in an attempt to block the highest number of in vivo-accessible target sites, for a prolonged period, we employed a combined (local and systemic) therapeutic regime. Animals were treated with purified L36 (20 mg/kg, day Ϫ1, n = 3) according to the following schedule: daily s.c. injections in the tissue adjacent to the tumor (during 20 days) and five i.v. injections (every second day starting at day 1). Control animals were injected with PBS (not shown) or an irrelevant scFv (B1.8) following the same regime. As seen in Figure 2b , tumor nodules grew detectably after the first 10 days in the control groups. By contrast, in the L36-treated group, the injected antibody delayed or inhibited tumor growth. Two of three of the scFv-treated mice were free of tumors at the time when all the control mice (PBS or B1.8 treated) had died from their tumor burden (Figure 2b and c) , and in the other mouse growth was only apparent by day 20 and coinciding with the end of treatment. Importantly the anti-laminin scFv appeared to be well tolerated by the mice, as no side-effects were observed at the doses used.
Figure 2 L36 recognizes laminin in tumor sections and inhibits tumor growth. (a) Paraffin sections of murine Lewis lung carcinoma (LLC) tumors stained with hematoxylin or immunostained with anti-CD31 mAb or anti-laminin scFv L36. Original magnifications, ×400. LLC cells (CRL-1642), were obtained from the ATCC and were grown in DMEM with 10% FCS. (b) Suppression of primary tumor growth. LLC cells (5 ×
To further investigate the effect of L36 scFv on established tumors, we used a plasmid-mediated gene therapy approach. 19, 20 Antibody genes (B1.8 and L36) were cloned into a hCMV-driven mammalian expression vector (pCR3.1) containing the human oncostatin M leader sequence (Figure 3a) . Transfection of human embryonic kidney 293T cells with plasmids pCR3.1-B1.8 or pCR3.1-L36 resulted in the secretion of functional scFv (B1.8 and L36, respectively) at significant levels. The secreted scFv bind specifically to its cognate antigen (NIP-BSA or laminin-1) as judged by ELISA (data not shown). Then, we tested if our genetic constructs allowed the expression of scFv by mouse LLC cells. Active scFv (B1.8 or L36) molecules were secreted into the cell culture supernatant of LLC cells transiently transfected with plasmid pCR3.1-B1.8 or pCR3.1-L36 (Figure 3b ). Immunohistochemical analysis revealed that L36 was expressed by tumor cells following direct intratumoral injection of naked plasmid DNA or DNA/liposomes complexes (Figure 3c and data not shown). The level of expression and labeling characteristics in vivo were similar in both cases (data not shown). Importantly intratumoral injection of pCR3.1-L36 (50 g/dose/every 48 h, n = 5) delayed significantly (P = 0.04) the growth rate of established Lewis lung tumors (Figure 3d) .
We next investigated the effect of persistent low and high L36 expression in a human tumor xenograft model. HT-1080 fibrosarcoma cells were stably transfected with episomal EBV-based vectors encoding scFv genes (B1.8 or L36). As expected, genetically modified tumor cells secreted the antibody fragment into the cell culture supernatant in a functional state (Figure 4a ). These stable transfectants (HT-B1.8 and HT-L36) were cloned and characterized for protein expression by ELISA. Clones secreting low and high levels of B1.8 and L36 were selected for further study (Figure 4b and c) . Microscopically, these clones were indistinguishable and had similar growth rates in vitro (data not shown). Selected clones were expanded in vitro and 10 6 cells of each clone were injected s.c. into the right flank of athymic nude mice (Figure 4d ). Our results demonstrate that higher persistent paracrine expression of L36 scFv resulted in the slower tumor growth. Low L36 expressing cells exhibited a considerable decrease in growth rate. Moreover, HT-1080 cell expressing high levels of L36 did not grow to a detectable size in any of the inoculated mice (Figure 4d ). Tumors from animals receiving HT-B1.8 transfectants (low and high expression) grew at a similar rate to that observed with parental HT-1080 cells (data not shown).
In summary we have demonstrated proof-of-principle for a novel cancer gene therapy strategy. Recent works have pointed out the therapeutic potential of scFv antibodies administered as protein and directed against angiogenic factors or used as a vehicle for the targeted delivery of anti-vascular agents. 21, 22 Going further, we have demonstrated the anti-tumoral effect of a locally produced ECM-blocking scFv. We have shown that if ECM surrounding endothelial cells may be rendered nonadhesive, by blocking a sufficient number of its functionally active domains, alignment of endothelial cells and tube formation would not occur. The efficient generation of non-permissive ECM will be dependent on accessibility, binding affinity and local concentration of antibody fragments. One way to improve the efficacy of this strategy would be to increase the functional affinity (avidity) of antibody molecules along with the use of cellbased carriers, which could target on tumors as a consequence of their normal functions and the biological properties of tumors. 23, 24 Gene Therapy for chick CAM assays; M Santos and M Fuente for animal care; I Millán for statistical analysis; and MJ de Pablos for expert secretarial assistance.
